Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

17 Feb 2020

Abstract excerpt

Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae , carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa , Stenotrophomonas maltophilia , and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics Pharmacokinetics and Efficacy
Share to Neutropenia and Cancer Infections
Share to Oral health in cancer treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32071053
DOI: 10.1128/aac.01955-19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of Cefiderocol and Comparators against Isolates from Cancer PatientsPMID 32071053Read ↗

In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinationsSemantic proximity Read ↗

In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsSemantic proximity Read ↗

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance ProgramSemantic proximity Read ↗

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii IsolatesSemantic proximity Read ↗

Activity of Cefiderocol Against Enterobacterales , Pseudomonas aeruginosa , and Acinetobacter baumannii Endemic to Medical Centers in New York CitySemantic proximity Read ↗

Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant MechanismsSemantic proximity Read ↗

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitorsSemantic proximity Read ↗

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging DataSemantic proximity Read ↗

Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and resistance to comparator agents.Semantic proximity Read ↗

Stability of cefiderocol against clinically significant broad-spectrum oxacillinasesSemantic proximity Read ↗

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant PathogensSemantic proximity Read ↗

In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.